Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan
FC Hsiao, CL Wang, PC Chang, YY Lu… - Journal of …, 2020 - journals.sagepub.com
Background: Angiotensin receptor neprilysin inhibitor (ARNI) was recommended by major
guidelines as the frontline therapy for heart failure with reduced ejection fraction (HFrEF)
since its clinical benefit was proved in the Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial.
However, little is known about its safety and effectiveness in real-world practice, often with
sicker and more fragile patients. In addition, East Asia population is underrepresented in …
guidelines as the frontline therapy for heart failure with reduced ejection fraction (HFrEF)
since its clinical benefit was proved in the Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial.
However, little is known about its safety and effectiveness in real-world practice, often with
sicker and more fragile patients. In addition, East Asia population is underrepresented in …
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Objective: Heart failure (HF) is a growing public health problem with high morbidity and
mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a
promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our
experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The
ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779
patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were …
mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a
promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our
experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The
ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779
patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were …